Contineum Therapeutics
San Diego, California, United States · Biopharma, Biotechnology, Health Care
Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. The company has a pipeline of internally-developed programs to address multiple NI&I disorders, primarily targeting biological pathways associated with specific clinical impairments. Contine
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (CTNM)
- Website
- www.contineum-tx.com
- Company page
Recent activity at Contineum Therapeutics
- : SEC 8-K (8.01): On September 14, 2026, Contineum Therapeutics, Inc. announced the results of the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 targeting major depressive disorder. The trial assessed the drug's efficacy, safety, and tolerability in adult participants. This drug is being developed by Johnson & Johnson under a global license and development agreement with Contineum, which is a significant collaboration for both companies in the mental health therapeutic area. The press release detailing the trial outcomes is attached as Exhibit 99.1.
- : SEC 8-K (7.01): On July 13, 2026, Contineum Therapeutics, Inc. updated its corporate presentation to reflect significant business and strategic updates. The updated presentation outlines recent developments and future plans which may influence stakeholder perceptions and investments. The presentation is attached as Exhibit 99.1 to the filing and will also be available on the company's website, indicating an ongoing effort to keep investors informed and engaged with the company's strategic direction. This update is crucial for stakeholders looking to assess the company's current positioning and future trajectory.
- : SEC 8-K (5.02): On January 23, 2026, the Board of Directors of Contineum Therapeutics, Inc. approved the 2026 Employment Inducement Equity Incentive Plan. This new plan shares similar terms with the 2024 Equity Incentive Plan, but prohibits the issuance of incentive stock options. The plan is specifically designed for eligible recipients in accordance with Nasdaq rules and was adopted without stockholder approval under Rule 5635(c)(4) of the Nasdaq Listing Rules. Initially, the Board has reserved 750,000 shares for this purpose, reflecting a strategic move to enhance talent acquisition and retention within the company.
- : Contineum Therapeutics Announces FDA Authorization for PIPE-791, Targeting Chronic Pain Treatment.
- : Contineum Therapeutics Appoints John Healy as General Counsel & Corporate Secretary
Leadership
- John Healy, General Counsel
Verified email and direct lines for Contineum Therapeutics’s decision-makers are on Fundz. See plans
Contineum Therapeutics in the news
- Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder - Yahoo Finance (Sep 14, 2026)
- Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - businesswire.com (Jun 01, 2026)
- Document - SEC.gov (May 06, 2026)
- Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain - businesswire.com (Apr 30, 2026)
- Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference - Yahoo Finance (Aug 25, 2026)
- Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry - Yahoo Finance (Jun 30, 2026)
- Contineum reroutes pipeline, funneling cash from MS to lung disease as it eyes showdown with BMS - Fierce Biotech (Aug 06, 2025)
- Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis - PNAS (Aug 12, 2025)
Companies similar to Contineum Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- YS Biopharma · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About Contineum Therapeutics: questions and answers
What does Contineum Therapeutics do?
Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. The company has a pipeline of internally-developed programs to address multiple NI&I disorders, primarily targeting biological pathways associated with specific clinical impairments. Contine
Where is Contineum Therapeutics headquartered?
Contineum Therapeutics is headquartered in San Diego, California, United States.
What is the latest news on Contineum Therapeutics?
On Sep 14, 2026, SEC 8-K (8.01): On September 14, 2026, Contineum Therapeutics, Inc. announced the results of the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 targeting major depressive disorder. The trial assessed the drug's efficacy, safety, and tolerability in adult participants. This drug is being de
Is Contineum Therapeutics a public company?
Yes. Contineum Therapeutics is publicly traded under the ticker CTNM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy